Last update 01 Nov 2024

IL-23 x OX40L x IL36G

Basic Info

Related Targets
IL-23OX40LIL36G

Related

1
Drugs associated with IL-23 x OX40L x IL36G
mRNA-2752
Target
IL-23 x IL36G x OX40L
Mechanism
IL-23 stimulants [+3]
Active Org.
AstraZeneca PLCAstraZeneca PLC
Originator Org.
Moderna, Inc.Moderna, Inc.
Active Indication
Melanoma [+5]
Inactive Indication
Hemophilia [+1]
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with IL-23 x OX40L x IL36G
NCT03739931 / Active, not recruitingPhase 1
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
NCT02872025 / RecruitingEarly Phase 1IIT
Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS
100 Clinical Results associated with IL-23 x OX40L x IL36G
Login to view more data
100 Translational Medicine associated with IL-23 x OX40L x IL36G
Login to view more data
0 Patents (Medical) associated with IL-23 x OX40L x IL36G
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free